Background and Aims: Oral drug delivery is the most attractive pathway for ulcerative colitis [UC] therapy, since it has many advantages. However, this strategy has encountered many challenges, including the instability of drugs in the gastrointestinal tract [GT], low targeting of disease tissues, and severe adverse effects. Nanoparticles capable of colitis tissue-targeted delivery and sitespecific drug release may offer a unique and therapeutically effective system that addresses these formidable challenges. Methods: We used a versatile single-step surface-functionalising technique to prepare PLGA/ PLA-PEG-FA nanoparticles loaded with the ginger active compound, 6-shogaol [NPs-PEG-FA/6-shogaol]. The therapeutic efficacy of NPs-PEG-FA/6-shogaol was evaluated in the well-established mouse model of dextran sulphate sodium [DSS]-induced colitis. Results: NPs-PEG-FA exhibited very good biocompatibility both in vitro and in vivo. Subsequent cellular uptake experiments demonstrated that NPs-PEG-FA could undergo efficient receptormediated uptake by colon-26 cells and activated Raw 264.7 macrophage cells. In vivo, oral administration of NPs-PEG-FA/6-shogaol encapsulated in a hydrogel system [chitosan/alginate] significantly alleviated colitis symptoms and accelerated colitis wound repair in DSS-treated mice by regulating the expression levels of pro-inflammatory [TNF-α, IL-6, IL-1β, and iNOS] and antiinflammatory [Nrf-2 and HO-1] factors. Conclusions: Our study demonstrates a convenient, orally administered 6-shogaol drug delivery system that effectively targets colitis tissue, alleviates colitis symptoms, and accelerates colitis wound repair. This system may represent a promising therapeutic approach for treating inflammatory bowel disease [IBD].
Introduction
Inflammatory bowel diseases [IBDs] , which include Crohn's disease [CD] and ulcerative colitis [UC] , are chronic debilitating inflammatory conditions. 1, 2 The conventional therapies currently used to treat IBD patients can fall into three groups: anti-inflammatory medications [such as aminosalicylates and corticosteroids], immunosuppressants, and antibiotics. [3] [4] [5] These medications can temporarily induce and maintain remission, but 80% and 45% of CD and UC patients, respectively, will require at least one surgical intervention in their lifetimes. 6, 7 Conventional oral formations [eg pellets, capsules, or tablets] are of limited use in IBD. These approaches, which are generally designed to achieve systemic delivery of therapeutics, can have many drawbacks including inefficacy, ineffective control of drug release, therapeutic variation due to IBD symptoms [eg diarrhoea and a modified colonic environment], and limit targeting of inflamed areas. Furthermore, the enhanced permeability that characterises the intact non-inflamed tissues of the upper intestinal tract in patients with IBD may mean that such drugs can have serious adverse effects. 8 Therefore, we need to develop novel carrier systems capable of delivering drugs specifically and exclusively to the inflamed regions associated with this disease. 9, 10 Among the novel carrier systems introduced in recent years, nanoparticles [NPs]-based drug-delivery systems [DDSs] are promising carriers for improving IBD therapy. Various DDSs [ie liposomes, mesoporous silica, and polymer NPs] have been rationally designed to be orally administered, release a loaded drug at a specific pH value, resist digestive enzymes, and/or require bacterial cleavage for activation. [11] [12] [13] [14] In general, these DDSs provide several substantial advantages over the conventional methods, such as by protecting the loaded drug against environmental degradation, improving drug solubility, enhancing absorption, and enabling sustained drug release. 15, 16 An NP-based delivery system can help the loaded drug specifically to accumulate at inflamed tissues, due to the increased permeability of such tissues. Furthermore, certain cell receptors or transporters that are over-expressed during the inflammatory response, such as CD44, 17 CD98, 18, 19 and folate receptor, 20, 21 can be exploited for active drug targeting. 22 Ginger [Zingiber officinale Roscoe] has been widely used as a spice, dietary supplement, and traditional medicine for centuries. [23] [24] [25] We recently demonstrated that a specific population of ginger-derived NPs may effectively reduce colitis, [26] [27] [28] [29] and showed that the major pharmacologically active compounds of these ginger NPs may be gingerols and shogaols. 6-shogaol, which is a major component of dried ginger, has received much attention because it has antioxidative, anti-inflammatory, and anticarcinogenic properties, 30, 31 and shows superior biological activity and enhanced stability compared with its counterpart in fresh ginger extract. However, it
is not yet known whether 6-shogaol could have therapeutic efficacy against UC.
In this study, we prepared folate-functionalised 6-shogaol loaded PLGA/PLA NPs [NPs-PEG-FA/6-shogaol] using a versatile singlestep surface-functionalising technique [as shown in Figure 1A ]. We first characterised their physicochemical properties [morphology, particle size, zeta potential, and drug release profile] and further evaluated their biocompatibility both in vitro and in vivo. Subsequent cellular uptake experiments demonstrated that NPs-PEG-FA could undergo efficient receptor-mediated uptake by colon-26 cells and activated Raw 264.7 macrophage cells. Our in vivo results showed that oral administration of NPs-PEG-FA/6-shogaol in a hydrogel system [chitosan/alginate] significantly alleviated colitis symptoms and accelerated colitis wound repair in DSS-treated colitic mice, by regulating the expression levels of pro-inflammatory [TNF-α, IL-6, IL-1β, and iNOS] and anti-inflammatory [Nrf-2 and HO-1] factors. This novel system may represent a promising therapeutic approach for treating IBD.
Methods

Materials
Lactide and added dropwise to the above emulsion with stirring. The emulsion was stirred overnight at room temperature, followed by 2 h of rotary evaporation under vacuum to remove the residual DCM. Nanoparticles were recovered by centrifugation [15 000 rpm, 15 min, at 4°C] and washed three times with de-ionised water. NPs suspension was then lyophilised to obtain a dry powder. DiL-or DiR-loaded nanoparticles involved the same procedures.
Preparation of NPs
Characterisation of NPs
The particle size and zeta potential of NPs-PEG and NPs-PEG-FA were determined using a Malvern Zetasiser Nano ZS90 Apparatus [Malvern Instruments, Malvern, UK] at room temperature. The morphology of NPs-PEG and NPs-PEG-FA was obtained using transmission electron microscopy [TEM] .
High performance liquid chromatography [HPLC] analysis was performed to evaluate 6-shogaol loading efficiency using an Agilent® 1100 LC System [Agilent Technologies Inc.; CA, USA]. The system was optimised in order to reduce dead volume and improve performance including: increasing the UV scan rate; changing the injector needle seat; re-plumbing the system with red PEEKsil™ Tubing [SGE] ; and using a semi-micro flow cell. The C18 column was from Phenomenex [Torrance, CA, USA]. All samples were dissolved in methanol/water [80:20] with 0.1 % trifluoroacetic acid [TFA] added as a stabiliser. Before injection, samples were filtered through a 0.45-µm syringe filter. The detection wavelength was set at 282 nm.
The release kinetics of 6-shogaol from NPs were carried out using Slide-A-Lyzer mini dialysis devices [MW 20k ]. Briefly, 10 mg of NPs-PEG or NPs-PEG-FA were dispersed in 10 mL phosphatebufferef saline [PBS] [pH 7.0]. The samples were shaken at 200 rpm at room tempreature. Aliquots were taken out from the dialysis bag at spectified time points [0, 4, 8, 24, 48 , and 72 h], and the release of 6-shogaol from NPs into the buffer solution was monitored via the HPLC method. 
Cell lines and cultures
Comparison of cellular uptake efficiency by flow cytometry
Colon-26 cells and activated Raw 264.7 macrophage cells with the concentration of 1 × 10 5 /well were seeded in six-well plates and incubated overnight. Cells were treated with NPs, NPs-PEG, NPs-PEG-FA-1, NPs-PEG-FA-2, and NPs-PEG-FA-3, respectively, [2 mg/ mL], which were all loaded with DiL. Here, cells treated with blank NPs without DiL loading were set as control. After incubating for different time periods [1, 3, and 5 h], the cells were rinsed with cooled PBS three times. Then, the treated cells were harvested for flow cytometry analysis. 
Folate receptor expression evaluation
Ulcerative colitis and UC wound-healing models
For the UC model, FVB/NJ mice were induced by adding 2.5% [w/v] dextran sodium sulphate [DSS] 36-50 kDa [MP Biomedicals; Santa Ana, CA, USA] in drinking water for 7 days. In experiment groups, mice were also orally administered NPs-PEG-FA/6-shogaol [equal to 15 mg/ kg 6-shogaol] in hydrogel, which comprised chitosan and alginate, [32] [33] [34] [35] and 6-shogaol [15 mg/kg] every day. The DSS solution was freshly prepared every other day. Body weight, faeces, and physical activity were monitored daily. After 7 days, mice were killed by CO 2 euthanasia, spleens were taken out and weighed, and small pieces of distal colon were collected for RNA analysis and histopathological analysis.
For the UC wound-healing model, mice were orally administrated 2.5% [w/v] dextran sodium sulphate [DSS] 36-50 kDa [MP Biomedicals; Santa Ana; CA, USA] in drinking water for 7 days, then were treated with NPs-PEG-FA/6-shogaol [equal to 15 mg/kg 6-shogaol] in hydrogel and 6-shogaol [15 mg/kg] for 7 days. the DSSgroup mice were only changed to regular water and without any treatment. Finally, mice were killed by CO 2 euthanasia and distal colons were collected for RNA analysis and histopathological analysis.
The choice of 6-shogaol [15 mg/kg] dosage is based on the human PK studies performed in the previous study, 36, 37 where free forms of ginger compounds including 6-shogaol were detected in the human blood plasma upon oral administration of 2 g ginger extract [GE] . Upon normalising for a 75 kg body weight, this 2 g GE is equivalent to 25 mg/kg. Given the faster metabolic rate in mice compared with humans and the allometric scaling factor of 10, 38 and the 6-shogaol abundance in GE, 39 we chose the dosage of 15 mg/kg for in vivo study.
Cellular internalisation of NPs-PEG-FA in vivo
To track NPs-PEG-FA in gastrointestinal [GI] tract after oral administration, near infrared dye, DiR, was employed as a fluorescence probe. Colitis was induced in FVB female mice by 2.5% [w/v] in water for 7 days. NPs-PEG-FA/DiR or NPs-PEG/DiR-embedded hydrogel was orally administered. After 6 and 12 h administration, GI tracts of mice were collected, and images were captured using IVIS in vivo imaging system [Perkin Elmer; Waltham, MA, USA].
Quantification of lipocalin-2
To quantify lipocalin-2 [Lcn-2], freshly collected mouse faeces were reconstituted in PBS containing 0.1% Tween 20 [50 mg/mL] and vortexed for 20 min to yield a homogeneous faecal suspension. Samples were then micro-centrifuged for 10 min at 4°C at full speed, and supernatants were collected for analysis [1: 20 dilution] . Levels of Lcn-2 were estimated using a Duoset mouse Lcn-2 ELISA kit [RandD Systems]. 
Monitoring of inflammation in vivo
Statistical analyses
One-way and two-way analyses of variance [ANOVA] and t-tests were used to determine statistical significance [*p < 0.05, **p < 0.01, ***p < 0.001].
Results
Preparation and characterisation of NPs-PEG-FA
We prepared NPs-PEG-FA using a versatile single-step surfacefunctionalising technique [ Figure 1A ]. PLA-PEG-FA block copolymer was added to a PLGA polymer/6-shogaol emulsion; due to the differential behaviour of the hydrophobic and hydrophilic segments of PLA-PEG-FA block copolymer at the oil/water interface, PLA-PEG-FA spontaneously localised to and oriented at the surfaces of the PLGA NPs. We then removed the organic solvent by evaporation to obtain NPs-PEG-FA. As shown in representative TEM images, NPs-PEG [ Figure 1B ] and NPs-PEG-FA [ Figure 1C ] were spherical in shape and exhibited narrow size distributions. We also used dynamic light scattering [DLS] to measure their particle sizes and zeta potentials. The average hydrodynamic diameters of NPs-PEG and NPs-PEG-FA were about 246.4 ± 0.8 nm and 249.6 ± 1.3 nm, respectively, and their zeta potentials were -29.37 ± 1.58 mV and -24.17 ± 0.41 mV, respectively. These data indicate that the morphology, size distribution, and zeta potential of the NPs were not significantly changed by the addition of the folate-conjugated copolymer.
We then encapsulated 6-shogaol in the NPs. HPLC revealed that the drug loading and encapsulation efficiencies of 6-shogaol in NPs-PEG-FA were 35.8 ± 7.2 µg/mg and 52 ± 3.4%, respectively [Supplementary Figure 1 , available as Supplementary data at ECCO-JCC online]. We investigated the release profiles of 6-shogaol from the NPs in vitro. As shown in Supplementary Figure 2 [available as Supplementary data at ECCO-JCC online], NPs-PEG and NPs-PEG-FA showed similar drug release profiles, with about 40% of the encapsulated 6-shogaol undergoing release from the NPs within the first 24 h. Both NPs-PEG and NPs-PEG-FA nanoparticles achieved cumulative 6-shogaol releases of about 80% over 72 h. These results indicate that 6-shogaol can migrate from the hydrophobic core of PLGA to the NP surface, to yield a sustained release profile and achieve controlled drug release. Figure 3D ]. This indicates that PEG modification increased the biocompatibility of the studied NPs.
Biocompatibility of NPs-PEG-FA in vitro and in vivo
To investigate the toxicity of NPs-PEG-FA in vivo, healthy mice were orally administered NPs-PEG-FA or PBS [control] for 7 days. At the end of the experiment [7 days treatment], body weight changes were compared, bloods were collected for haematological and biochemical analyses, and tissues from the gastrointestinal [GI] tract and major organs [heart, liver, spleen, lung, and kidney] were collected for histological analysis. There was no remarkable difference in the body weight change, haematological parameters, or biochemical findings of the NPs-PEG-FA-treated mice compared with controls [ Figure 2A -C]. We also failed to find any notable sign of toxicity in tissues from the GI tract [ Figure 2D ] or heart, liver, spleen, lung, or kidney [ Supplementary Figure 4 , available as Supplementary data at ECCO-JCC online]. These data indicate that NPs-PEG-FA do not appear to have any obvious toxicity in vivo. Taken together, our findings indicate that NPs-PEG-FA exhibit excellent biocompatibility in vitro and in vivo, and thus could be safely used as a drug delivery vehicle.
NPs-PEG-FA are taken up by macrophages and epithelial cells
Efficient cellular uptake of NPs is a major requirement for their therapeutic efficacy. Folate has been shown to increase the cellular uptake of nanocarrier systems by targeting the folate receptor. [40] [41] [42] [43] To confirm the activity of the folate molecules on the surfaces of NPs-PEG-FA, we performed in vitro cell uptake studies using fluorescently Figure 3A , a and c]. These results suggest that folate receptor could be involved in the uptake of folate-functionalised NPs but not in that of non-targeted NPs. Cellular uptake was also assessed by flow cytometry, which revealed much stronger fluorescence in colon-26 cells [ Figure 3B ] and activated Raw 264.7 cells [ Figure 3C ] treated with NPs-PEG-FA versus NPs-PEG. These results are consistent with the idea that NPs-PEG-FA undergoes folate-receptor-mediated endocytosis.
We further used flow cytometry to compare the cellular uptake efficiencies of NPs-PEG-FA with three different amounts of surfacedisplayed FA. Here, NPs-PEG-FA-1, 2, and 3 were defined as 10%, 15%, and 20% [w/w] of PLA-PEG-FA in total polymers. As shown in Figure 4 , the various NPs were incubated with colon-26 cells and activated Raw 264.7 cells for 1, 3, and 6 h. NPs-PEG-FA-1 exhibited a higher internalisation efficiency in colon-26 cells, whereas NPs-PEG-FA-1, -2, and -3 had similar internalisation efficiencies in activated Raw 264.7 cells. These results indicated that surface functionalisation with FA enabled the NPs to experience an enhanced cellular uptake that was directly related to the amount of surfacefunctionalised FA. These data are consistent with previous reports. 42 Based on our findings, we used NPs-PEG-FA-1 for the following experiments.
The uptake of NPs-PEG-FA by the intestinal mucosa is increased during colitis
The accumulation of NPs in the colon region is one the most important features of an effective nanomedicine for colon diseases, such as ulcerative colitis [UC] . To achieve such accumulation, we encapsulated NPs-PEG-FA in a hydrogel system comprising alginate/chitosan with a special weight ratio [3/7] . Our previous research showed that this hydrogel system can deliver and release encapsulated nanoparticles to the colon region in response to the specific pH found in the colon. [32] [33] [34] [35] To investigate the in vivo biodistribution of NPs-PEG-FA in the GI tract, we orally dosed DSS-treated colitic mice with DiRloaded NPs-PEG-FA in our hydrogel system, and used an in vivo imaging system [IVIS] to examine the near-infrared fluorescence of DiR in the GI tract at 6 h and 12 h post-administration [ Figure 5A ]. We found that colitic mice treated with NPs-PEG-FA/DiR exhibited significantly stronger DiR fluorescence intensity in the colon compared with NPs-PEG/DiR-treated mice, at both 6 h and 12 h post-administration [ Figure 5B ]. Fluorescence imaging of colitis tissues also confirmed that oral administration of NPs-PEG-FA in the hydrogel system resulted in the delivery of NPs-PEG-FA to the colon and their uptake by colonic cells [ Figure 5C ]. The expression of folate receptor was enhanced in colitis tissues [Supplementary Figure 6 , available as Supplementary data at ECCO-JCC online], allowing us to conclude that the enhanced colitis tissue uptake of NPs-PEG-FA appears to reflect receptor-mediated endocytosis.
Oral administration of NPs-PEG-FA/6-shogaol attenuates UC
Having confirmed that NPs-PEG-FA in our hydrogel system can preferentially target the colon, we next assessed whether NPs-PEG-FA/6-shogaol can attenuate DSS-induced UC, which is a well-established mouse model for studying human UC. 44, 45 Mice were provided with DSS-laced water for 7 days with or without simultaneous daily oral administration of NPs-PEG-FA/6-shogaol or 6-shogaol. To assess the progression of intestinal inflammation, we used ELISA to assess the faecal levels of lipocalin-2 [Lcn-2], which is a widely accepted biomarker for intestinal inflammation. 46 As shown in Figure 6A , the basal levels of Lcn-2 in the different treatment groups were similarly low on Day 1 to Day 3. In the DSS and DSS plus 6-shogoal groups, the Lcn-2 level dramatically increased beginning on Day 5. By comparison, the Lcn-2 level in the DSS plus NPs-PEG-FA/6-shogaol group was significantly lower than the levels in the DSS control and DSS plus 6-shogoal groups on Day 5 and thereafter. These results suggest that NPs-PEG-FA/6-shogaol exerts excellent anti-inflammatory effects and appears to attenuate DSS-induced UC.
To further assess treatment effects at a quantitative level, we employed in vivo bioluminescence imaging using the inflammation probe [XenoLight TM ; MA, USA], 47, 48 which allowed us to longitudinally track the myeloperoxidase [MPO] level and inflammation status in vivo. As shown in Figure 6B and C, DSS treatment was associated with an increased bioluminescence signal that reflected severe intradigestive inflammation. However, and consistent with our Lcn-2 data, this bioluminescence signal was significantly lower in DSS plus NPs-PEG-FA/6-shogaol-treated mice versus the DSS control group.
At the end of the experiment, mice were sacrificed. We found that those treated with NPs-PEG-FA/6-shogaol exhibited significantly decreased spleen/body weight [ Figure 6D ], indicating reduced inflammation with NPs-PEG-FA/6-shogaol treatment. The histological effects of NPs-PEG-FA/6-shogaol on DSS-induced UC were examined by haematoxylin and eosin [H＆E] staining. Mice treated with DSS alone exhibited robust signs of inflammation, including epithelial erosion, interstitial oedema, and a general increase in the number of inflammatory cells in the lamina propria [ Figure 6E , b, arrowhead]. In contrast, mice treated with DSS plus NPs-PEG-FA/6-shogaol showed decreases in these signs of UC at the histological level, including a particularly notable decrease of local lymphocytic infiltration [ Figure 6E , d].
We also determined the mRNA expression levels of pro-and anti-inflammatory genes in the different treatment groups. As shown in Figure 6F , the expression levels of the pro-inflammatory genes, TNF-α, IL-6, IL-1β, and iNOS, were increased significantly in DSS-treated mice, whereas these increases were significantly ameliorated in the DSS plus NPs-PEG-FA/6-shogaol group. Treatment with NPs-PEG-FA/6-shogaol was also associated with increase in the anti-inflammatory genes, nuclear factor [erythroidderived 2]-like 2 [Nrf-2], and haeme oxygenase [HO-1]. These findings indicate that NPs-PEG-FA/6-shogaol confers anti-inflammatory effects against DSS-induced colitis by blocking the production of damaging pro-inflammatory genes while enhancing the production of anti-inflammatory genes.
Oral administration of NPs-PEG-FA/6-shogaol accelerates colitis wound repair
The ability of modulatory factors to enhance intestinal repair mechanisms may form the basis of future approaches for treating diseases characterised by injury to the epithelial surface. 49 Based on our finding that simultaneously administered NPs-PEG-FA/6-shogaol could attenuate DSS-induced UC, we next tested whether NPs-PEG-FA/6-shogaol could help heal the inflamed mucosa when applied subsequent to the administration of DSS. As shown in Figure 7A , colitis was induced by DSS from Day 1-Day 7 [colitis phase], and recovery was from Day 7-Day 13 [recovery phase] induced by plain water, NPs-PEG-FA/6-shogaol, and free 6-shogaol, respectively. The Lcn-2 levels of mice treated with DSS alone gradually increased from Day 1 to Day 7 and thereafter remained high, indicating active intestinal inflammation. In contrast, mice treated with DSS followed by NPs-PEG-FA/6-shogaol had lower Lcn-2 levels than the DSS group from Day 7-Day 13 and had almost completely recovered their pretreatment Lcn-2 levels at Day 13. This was further confirmed by in vivo bioluminescence imaging using an inflammation probe [XenoLight TM ; MA, USA]. As shown in Figure 7B , mice of the NPs-PEG-FA/6-shogaol group displayed significantly lower luminescence intensity on Day 13, at a level that indicated the presence of only negligible inflammation in the GI tract. Similarly, histological analysis confirmed that the ulceration of the intestinal mucosa and the extent of neutrophil infiltration were lower in NPs-PEG-FA/6-shogaol-treated mice [ Figure 7C ]. Finally, in NPs-PEG-FA/6-shogaol-treated mice, the mRNA expression levels of certain pro-inflammatory cytokines [TNF-α, IL-6, IL-1β] and iNOS were significantly decreased at the end of the recovery phase, whereas that of Nrf-2 [no significant difference of HO-1] was enhanced [ Figure 7D ] relative to the control group, suggesting that oral administration of NPs-PEG-FA/6-shogaol could accelerate colitis wound repair by regulating gene expression.
Discussion
The development of colon-targeted oral delivery systems represents an active area of research for treating diseases that affect the colon, particularly ulcerative colitis [UC]. The existing strategies for colontargeted delivery include pH-dependent, time-dependent, and microflora-enzyme dependent systems. Although pH-dependent systems may survive passage through the stomach, 50 time-dependent systems usually depend on the typical duration it takes food and drugs to passage through the GI tract, which can be irregular especially in disease states. 51 Recently, nanotechnology has emerged as a novel and efficient tool for targeted drug delivery. Upon oral administration, nanoparticle-based drug delivery systems [DDSs] may protect a loaded drug from the harsh gastrointestinal environment and selectively increase the concentration of the drug at the disease site.
Among the developed NPs, polymeric NPs, especially those formulated using lactide:glycolide [PLGA] copolymer, have emerged as promising carriers for the targeted colonic delivery of various payloads, including drugs, siRNAs, and proteins. PLGA NPs have the advantages of biodegradability, biocompatibility, ease of formulation, and tunable sustained drug release properties. 52, 53 However, a striking drawback for PLGA NPs is the limited number of surface-displayed functional groups that may be employed for targeting ligands. 54, 55 In the present work, we took full advantage of the differential behaviour of the hydrophobic and hydrophilic segments of PLA-PEG-FA block copolymers at the oil/water interface. This enabled folate-functionalised PLGA/PLA-PEG-FA NPs to be easily fabricated using a versatile single-step surface-functionalising technique. Critically, our PEG-chain-modified NPs exhibited excellent biocompatibility in vitro and in vivo, indicating they can be used as a safe drug delivery carrier.
Ginger, which shows anti-inflammatory and anti-oxidative properties, has long been used in traditional medicine to treat numerous ailments, including digestive issues [indigestion, constipation, and ulcers] and degenerative disorders [arthritis and rheumatism]. 56, 57 A major component of dried ginger, 6-shogaol, has been a prime focus of the in vitro research related to the anti-inflammatory effects of ginger. However, there has not been any systematic study of the in vivo anti-inflammatory effects of 6-shogaol, especially in the context of inflammatory bowel diseases [IBDs] . In the present work, we show that 6-shogaol loaded in a colon-targeting delivery carrier appears to significantly alleviate colitis symptoms and accelerate colitis wound repair in the DSS-induced mouse model of colitis. Mechanistically, our real-time PCR results indicate that 6-shogaol exerts its anti-inflammatory effects by regulating several important molecular targets. It suppresses several pro-inflammatory cytokines [TNF-α, IL-6, and IL-1β] that are characteristically upregulated in DSS-induced colitis, 58 as well as inducible nitric oxide synthase [iNOS], which produces nitric oxide [NO] and is involved in the pathogenesis of colitis. 59 Conversely, 6-shogaol promotes the expression of nuclear factor [erythroid-derived 2]-like 2 [Nrf-2] and haeme oxygenase 1 [HO-1], which play important roles in anti-inflammation and anti-oxidation. [60] [61] [62] The potential anti-inflammatory mechanisms of 6-shoagol in IBD have not been systematically demonstrated yet. However, the clear mechanisms of 6-shogaol in other systems could benefit us as background. For example, Chen et al. identified Nrf-2 as a molecular target of 6-shogaol in colon epithelial cells both in vitro and in vivo, and they demonstrated that 6-shogaol induced nuclear translocation of Nrf-2 and activated Nrf-2 target genes in an Nrf-2-dependent manner. 61 Mitogen-activated protein kinases [MAPKs] have been associated with the Nrf-2 pathway in an inducer-and cell type-dependent manner. 63 PI3K have also been extensively investigated for its regulation of Nrf-2.
64,65 These findings suggest that MAPKs and the PI3K/AKT pathway participate in 6-shogaol induced Nrf-2 activation in HCT-116 cells. Luettig et al. confirmed that 6-shogaol has barrier-protective effects by affecting TNF-α induced claudin-2 upregulation and claudin-1 disassembly via inhibition of PI3K/AKT and NF-κB light chain enhancer of activated B-cell signalling, suggesting 6-shogaol might be beneficial for barrier preservation during intestinal inflammation. 58 In addition, the proposed mechanism behind 6-shogaol inhibition of NO evolution in stimulated macrophages involves downregulation of inflammatory iNOS and COX-2 gene expression by inhibition of the activation of NF-κB, because NF-κB plays a critical role in the coordination of the expressions of pro-inflammatory enzymes 66 ; inhibition of DNA-binding activity of NF-κB corresponds to the expressional inhibition of iNOS, COX-2, and TNF-α. 67 In summary, we herein used a versatile single-step surfacefunctionalising technique to prepare 6-shogaol-loaded PLGA/PLA-PEG-FA nanoparticles [NPs-PEG-FA/6-shogaol], and found that this NP exerts excellent biocompatibility both in vitro and in vivo. Furthermore, we show that oral administration of NPs-PEG-FA/6-shogaol in a hydrogel system could significantly alleviate colitis symptoms and accelerate colitis wound repair in DSS-induced mouse colitis. This system may represent a promising therapeutic approach for treating IBD. 
